<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02413138</url>
  </required_header>
  <id_info>
    <org_study_id>J14VR5</org_study_id>
    <nct_id>NCT02413138</nct_id>
  </id_info>
  <brief_title>Versartis Trial in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD) to Assess Long-Acting Growth Hormone (Somavaratan, VRS-317)</brief_title>
  <official_title>A Randomized, Phase 2/3, Open-Label, Multi-center Study of the Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of A Long-acting Human Growth Hormone (Somavaratan, VRS-317) in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Versartis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Versartis Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial will consist of three stages: 1) a 30 day Phase 2 PK and PD evaluation of
      somavaratan, 2) an optional Phase 2 Extension and 3) a 12 month Phase 3 safety and efficacy
      stage. Upon completion of the PK/PD stage, the PK/PD profiles for the GHD children in this
      study will be compared to the PK/PD profiles for the GHD children treated in the Western
      study Phase 1b/2a study (Protocol 12VR2) and identify the somavaratan dose to be used in the
      Phase 3 stage in Japan. The Phase 3 stage will continue dosing for 12 months to obtain safety
      and efficacy data on 48 subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial will consist of three stages: 1) a 30 day Phase 2 PK and PD evaluation of
      somavaratan, 2) an optional Phase 2 Extension and 3) a 12 month Phase 3 safety and efficacy
      stage. The study is a randomized, multi-center, open label study. The primary endpoint is
      height velocity at 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The primary endpoint of non-inferiority to daily therapy in the pediatric Phase 3 study was not
    achieved
  </why_stopped>
  <start_date type="Actual">August 8, 2015</start_date>
  <completion_date type="Actual">November 30, 2017</completion_date>
  <primary_completion_date type="Actual">November 30, 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy (Annual Height velocity)</measure>
    <time_frame>12 months</time_frame>
    <description>Annual Height velocity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (IGF-I responses to study drug administration)</measure>
    <time_frame>12 months</time_frame>
    <description>IGF-I responses to study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (IGFBP-3 responses to study drug administration)</measure>
    <time_frame>12 months</time_frame>
    <description>IGFBP-3 responses to study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (Number of subjects with adverse events )</measure>
    <time_frame>12 months</time_frame>
    <description>Number of subjects with adverse events (including repeat dose immunogenicity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (Concomitant medications)</measure>
    <time_frame>12 months</time_frame>
    <description>Concomitant medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (Safety labs)</measure>
    <time_frame>12 months</time_frame>
    <description>Safety labs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (Vital signs)</measure>
    <time_frame>12 months</time_frame>
    <description>Vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (Physical Exams)</measure>
    <time_frame>12 months</time_frame>
    <description>Physical Exams</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Secondary Efficacy (Change in height SDS)</measure>
    <time_frame>12 months</time_frame>
    <description>Change in height SDS.</description>
  </other_outcome>
  <other_outcome>
    <measure>Secondary Efficacy</measure>
    <time_frame>12 months</time_frame>
    <description>Change in body weight</description>
  </other_outcome>
  <other_outcome>
    <measure>Secondary Efficacy</measure>
    <time_frame>12 months</time_frame>
    <description>Change in body mass index.</description>
  </other_outcome>
  <other_outcome>
    <measure>Secondary Efficacy (Change in bone age)</measure>
    <time_frame>12 months</time_frame>
    <description>Change in bone age.</description>
  </other_outcome>
  <other_outcome>
    <measure>Secondary Efficacy (Change in pubertal staging.)</measure>
    <time_frame>12 months</time_frame>
    <description>Change in pubertal staging.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Pediatric Growth Hormone Deficiency</condition>
  <condition>Growth Disorders</condition>
  <arm_group>
    <arm_group_label>Phase 2: Somavaratan (VRS-317)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active treatment arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 3: Somavaratan (VRS-317)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Somavaratan long acting recombinant human growth hormone administered subcutaneously twice-monthly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somavaratan (VRS-317)</intervention_name>
    <description>Long acting recombinant human growth hormone</description>
    <arm_group_label>Phase 2: Somavaratan (VRS-317)</arm_group_label>
    <arm_group_label>Phase 3: Somavaratan (VRS-317)</arm_group_label>
    <other_name>Long acting recombinant human growth hormone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronological Age ≥ 3.0 years and ≤ 9.0 years (girls) or ≤ 10.0 years (boys)

          -  Pre-pubertal status

          -  Diagnosis of GHD as documented by two or more GH stimulation test results

          -  Height SD score ≤ -2.0 at screening

          -  Weight for Stature ≥ 10th percentile

          -  IGF-I SD score ≤ -1.0 at screening

          -  Delayed bone age

        Exclusion Criteria:

          -  Prior treatment with any growth promoting agent

          -  History of, or current, significant disease

          -  Chromosomal aneuploidy, significant gene mutations (other than those that cause GHD)
             or confirmed diagnosis of a named syndrome

          -  Birth weight and/or birth length less than 5th percentile for gestational age

          -  A diagnosis of Attention Deficit Hyperactivity Disorder

          -  Daily use of anti-inflammatory doses of glucocorticoid

          -  Prior history of leukemia, lymphoma, sarcoma or cancer

          -  Ocular findings suggestive of increased intracranial pressure and/or retinopathy at
             screening

          -  Significant spinal abnormalities including scoliosis, kyphosis and spina bifida
             variants

          -  Significant abnormality in screening laboratory studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Will Charlton, MD</last_name>
    <role>Study Director</role>
    <affiliation>Vesrartis</affiliation>
  </overall_official>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2015</study_first_submitted>
  <study_first_submitted_qc>April 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2015</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GHD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocrine System Diseases</mesh_term>
    <mesh_term>Dwarfism, Pituitary</mesh_term>
    <mesh_term>Growth Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

